1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Cellular Senescence Network (SenNet): Technology Projects (UG3/UH3 Clinical Trial Not Allowed)" is currently closed and not accepting applications.
Cellular Senescence Network (SenNet): Technology Projects (UG3/UH3 Clinical Trial Not Allowed) is sponsored by NIH Common Fund, National Institute on Aging, National Cancer Institute.
This program solicits applications for Stage 2 of the Cellular Senescence Network (SenNet) Program, which seeks to understand the biological consequences of senescent cell heterogeneity in health and disease, identify and characterize tissue-specific senescence markers in human biospecimens, and facilitate the development of senotherapeutic strategies that improve health outcomes.
Senolytic dasatinib quercetin research directly aligns with the program's goals.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Cellular Senescence Network (SenNet):Technology Projects (UG3/UH3 Clinical Trial Not Allowed) Cellular Senescence Network (SenNet):Technology Projects (UG3/UH3 Clinical Trial Not Allowed) Agency: National Institutes of Health Assistance Listings: 93. 310 -- Trans-NIH Research Support Last Updated: May 28, 2025 View version history on Grants.
gov The NIH Common Fund, National Institute on Aging, National Cancer Institute and additional NIH Institutes and Centers (ICs) intend to publish a Notice of Funding Opportunity (NOFO) to solicit applications for Stage 2 of the Cellular Senescence Network (SenNet) Program, which seeks to understand the biological consequences of senescent cell heterogeneity in health and disease, identify and characterize tissue-specific senescence markers in human biospecimens to facilitate the development of senotherapeutic strategies that improve health outcomes.
The program’s Senescence Technology Projects (SenTecs) will develop innovative tools and technologies that consider the complex nature of senescence to facilitate identification, characterization and targeting of senotypes in vivo. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
This NOFO will utilize the UG3/UH3 activity code. Investigators with expertise and insights into the cellular senescence impact on human health, the development of technologies and computational tools to identify and characterize senescent cells and inform novel approaches for the strategic targeting of senescent cells in vivo are encouraged to apply in response to these new NOFOs.
Other Native American tribal organizations Nonprofits non-higher education with 501(c)(3) Federally recognized Native American tribal governments Public and Indian housing authorities For-profit organizations other than small businesses Private institutions of higher education Independent school districts Public and state institutions of higher education Grantor contact information Office of Strategic Coordination, DPCPSI, OD No documents are currently available.
Link to additional information Estimated Application Due Date : Estimated Due Date Description : Estimated Project Start Date : Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity :
According to the current listing, eligibility includes: Investigators with expertise and insights into the cellular senescence impact on human health, the development of technologies and computational tools to identify and characterize senescent cells, and inform novel approaches for the strategic targeting of senescent cells in vivo are encouraged to apply. Confirm the full requirements in the official notice before applying.
The current listing shows $6,000,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was May 28, 2025, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Cellular Senescence Network (SenNet): Technology Projects (UG3/UH3 Clinical Trial Not Allowed) is funded by NIH Common Fund, National Institute on Aging, National Cancer Institute. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NOT-RM-26-004 asks the public for NIH-wide research challenges worth a 10-year, cross-institute program. There is no budget, no biosketch, no page limit, and no award. What there is: the five criteria every Common Fund investment has met since 2006, a new bullet about small-lab burden, and a fund whose FY 2026 request came in at $347.4 million — down 49.3 percent.
Read articleThe NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read articleAvoid common NIH grant proposal mistakes including vague specific aims, weak methodology, and poor budget justification that lead to rejection.
Read article